1151 ET - Tilray's recent run of weak Canadian adult-use cannabis sales should start to turn around now that the company has completed capital investments aimed at sprucing up its participation in the vape and infused pre-roll categories, TD Cowen analysts say in a research note. The company had been choosing not to participate in the two categories, which carry higher taxes and lower margins, as they were seeing significant price deflation across the industry, the analysts say. But Tilray recently invested in a facility that allows it to use more cannabis byproducts as inputs for vapes and infused pre-rolls, allowing for better economies of scale, they say. The facility is now operational, so adult-use trends should improve sequentially in 3Q, the analysts say. (dean.seal@wsj.com)
(END) Dow Jones Newswires
January 14, 2025 11:51 ET (16:51 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。